Mycophenolate After Stem Cell Transplant for Systemic Sclerosis

Starting soon · Phase 2

Conditions studied: Systemic Sclerosis (SSc)

In brief

A pilot single center randomized trial to test whether a full-scale RCT evaluating the role of post-AHSCT maintenance immunosuppression with MMF in preventing disease relapse is feasible . We are studying whether a brief course of treatment with MMF after AHSCT will serve to prevent disease relapse.

Key facts

Study ID

NCT07734012

Run by

Ottawa Hospital Research Institute

People needed

6

Starts

2026-08-01

Expected to finish

2029-12-01

Last updated by the study team

2026-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Consenting participants 18 years of age or older who are initiating AHSCT at The Ottawa Hospital for management of SSc.

You may not qualify if…

• Exclusion criteria are focused on patient safety, namely inability to receive treatment with
• MMF due to contraindications as determine at time of randomization (day 90 / clinic visit #3) including:
• Renal insufficiency (eGFR <25 mL/minute/1.73m2) or
• Neutropenia (ANC <1.0 x 103/mcL) or
• Thrombocytopenia (platelet count <50 000/mcL)
• Previously documented intolerance.
• Pregnant or breastfeeding - Women of childbearing potential who are not willing to use a highly effective method of contraception for the duration of study participation will be excluded

Where it is running

• The Ottawa Hospital — Ottawa, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.